Liliya Zhukova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liliya Zhukova has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Wysłouch-Cieszyńska
Affiliation: Department of Biophysics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
6 shared publications - Igor Zhukov
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland
5 shared publications - Maciej Kozak
Department of Macromolecular Physics, Faculty of Physics, Adam Mickiewicz University in Poznań, Poznań, Poland
4 shared publications - Astrid Gräslund
Department of Biochemistry and Biophysics, Stockholm University, 106 91 Stockholm, Sweden
3 shared publications - Maciej Gielnik
Department of Molecular Biology and Genetics, Aarhus University, Denmark
3 shared publications - Edyta Mikuła
Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Tuwima Str. 10, 10-748 Olsztyn, Poland
2 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (7) , 113226
A closely related pair of superoxide dismutase isozymes from Staphylococcus aureus show distinct stabilities and proton-exchange dynamics
- 5 June 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (7) , 113226
Open AccessA closely related pair of superoxide dismutase isozymes from Staphylococcus aureus show distinct stabilities and proton-exchange dynamics
- 13 December 2025
- Published by Elsevier in Journal of Structural Biology
- Vol. 218 (1) , 108280
Solution 3D structure and conformational flexibility of the endothelial monocyte activating polypeptide II (EMAP II) revealed by NMR spectroscopy and molecular dynamics simulations
- 13 December 2025
- Published by Elsevier in Journal of Structural Biology
- Vol. 218 (1) , 108280
Solution 3D structure and conformational flexibility of the endothelial monocyte activating polypeptide II (EMAP II) revealed by NMR spectroscopy and molecular dynamics simulations
- Open Access
- 27 March 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-20
The molecular properties of the bHLH TCF4 protein as an intrinsically disordered hub transcription factor
Background: Transcription factor 4 (TCF4) is a member of the basic helix-loop-helix (bHLH) family of transcription factors that guides proper embryogenesis, particularly neurogenesis, myogenesis, heart development and hematopoiesis. The interaction of TCF4 with DNA is dependent on the presence of a conserved bHLH domain, particularly the presence of a basic (b) motif. Most mutations in the Tcf4 gene are either associated with the development of serious nervous system disorders, such as Pitt-Hopkins syndrome or schizophrenia, or are lethal. Although TCF4 is essential for the proper development and function of the human body, there is a lack of fundamental knowledge about the structure of TCF4 since structural studies were previously limited exclusively to its bHLH. Methods: Recombinant full-length TCF4 was expressed in bacterial cells and purified using chromatographic techniques. To compare the properties of TCF4 in its apo and holo form, we determined the dissociation constant (KD) of the TCF4:DNA complex using independent methods, including fluorescence polarization (FP), electrophoretic mobility shift assay (EMSA), and fluorescence correlation spectroscopy (FCS). Then we compared the properties of TCF4 in its apo and holo form in relation to the changes of the conformation of the polypeptide chain (hydrogen/deuterium exchange mass spectrometry; HDX-MS), hydrodynamic properties (e.g., sedimentation-velocity analytical ultracentrifugation; SV-AUC), and stability (thermal shift, circular dichroism; CD). Results: We demonstrate the molecular characteristics of TCF4, the dimer of which is one of the largest intrinsically disordered proteins (IDPs) described to date. According to our findings, the structure of TCF4 is extensively disordered. Only the bHLH domain exhibits a stable fold. Strikingly, Ephrussi-box (E-box) binding via the bHLH domain has no significant effect on the disordered nature of TCF4, but it does influence the dynamic of bHLH and stability of the protein. Conclusions: We suggest that bHLH plays the role of an anchor localizing TCF4 to specific gene sequences. The dual nature of the TCF4 structure and the fact that the intrinsically disordered regions (IDRs) represent most of the protein sequence, suggest that TCF4 may act as a hub transcription factor regulating the expression of specific genes through the interaction of IDRs with gene-specific partners.
- 27 March 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-20
Open AccessThe molecular properties of the bHLH TCF4 protein as an intrinsically disordered hub transcription factor
Background: Transcription factor 4 (TCF4) is a member of the basic helix-loop-helix (bHLH) family of transcription factors that guides proper embryogenesis, particularly neurogenesis, myogenesis, heart development and hematopoiesis. The interaction of TCF4 with DNA is dependent on the presence of a conserved bHLH domain, particularly the presence of a basic (b) motif. Most mutations in the Tcf4 gene are either associated with the development of serious nervous system disorders, such as Pitt-Hopkins syndrome or schizophrenia, or are lethal. Although TCF4 is essential for the proper development and function of the human body, there is a lack of fundamental knowledge about the structure of TCF4 since structural studies were previously limited exclusively to its bHLH. Methods: Recombinant full-length TCF4 was expressed in bacterial cells and purified using chromatographic techniques. To compare the properties of TCF4 in its apo and holo form, we determined the dissociation constant (KD) of the TCF4:DNA complex using independent methods, including fluorescence polarization (FP), electrophoretic mobility shift assay (EMSA), and fluorescence correlation spectroscopy (FCS). Then we compared the properties of TCF4 in its apo and holo form in relation to the changes of the conformation of the polypeptide chain (hydrogen/deuterium exchange mass spectrometry; HDX-MS), hydrodynamic properties (e.g., sedimentation-velocity analytical ultracentrifugation; SV-AUC), and stability (thermal shift, circular dichroism; CD). Results: We demonstrate the molecular characteristics of TCF4, the dimer of which is one of the largest intrinsically disordered proteins (IDPs) described to date. According to our findings, the structure of TCF4 is extensively disordered. Only the bHLH domain exhibits a stable fold. Strikingly, Ephrussi-box (E-box) binding via the bHLH domain has no significant effect on the disordered nature of TCF4, but it does influence the dynamic of bHLH and stability of the protein. Conclusions: We suggest that bHLH plays the role of an anchor localizing TCF4 to specific gene sequences. The dual nature of the TCF4 structure and the fact that the intrinsically disordered regions (IDRs) represent most of the protein sequence, suggest that TCF4 may act as a hub transcription factor regulating the expression of specific genes through the interaction of IDRs with gene-specific partners.
- Open Access
- 10 February 2022
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 69 (1) , 257-261
The engineered peptide construct NCAM1-Aβ inhibits fibrillization of the human prion protein (PrP)
In prion diseases, the prion protein (PrP) becomes misfolded and forms fibrillar aggregates that are responsible for prion infectivity and pathology. So far, no drug or treatment procedures have been approved for prion disease treatment. We have previously shown that engineered cell-penetrating peptide constructs can reduce the amount of prion aggregates in infected cells. However, the molecular mechanism underlying this effect is unknown. Here, we use atomic force microscopy (AFM) imaging to show that the amyloid aggregation and fibrillization of the human PrP protein can be inhibited by equimolar amounts of the 25 residues long engineered peptide construct NCAM1-Aβ.
- 10 February 2022
- Published by Frontiers Media SA in Acta Biochimica Polonica
- Vol. 69 (1) , 257-261
Open AccessThe engineered peptide construct NCAM1-Aβ inhibits fibrillization of the human prion protein (PrP)
In prion diseases, the prion protein (PrP) becomes misfolded and forms fibrillar aggregates that are responsible for prion infectivity and pathology. So far, no drug or treatment procedures have been approved for prion disease treatment. We have previously shown that engineered cell-penetrating peptide constructs can reduce the amount of prion aggregates in infected cells. However, the molecular mechanism underlying this effect is unknown. Here, we use atomic force microscopy (AFM) imaging to show that the amyloid aggregation and fibrillization of the human PrP protein can be inhibited by equimolar amounts of the 25 residues long engineered peptide construct NCAM1-Aβ.
- Open Access
- 4 November 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
Zn(II) binding causes interdomain changes in the structure and flexibility of the human prion protein
The cellular prion protein (PrPC) is a mainly α-helical 208-residue protein located in the pre- and postsynaptic membranes. For unknown reasons, PrPC can undergo a structural transition into a toxic, β-sheet rich scrapie isoform (PrPSc) that is responsible for transmissible spongiform encephalopathies (TSEs). Metal ions seem to play an important role in the structural conversion. PrPC binds Zn(II) ions and may be involved in metal ion transport and zinc homeostasis. Here, we use multiple biophysical techniques including optical and NMR spectroscopy, molecular dynamics simulations, and small angle X-ray scattering to characterize interactions between human PrPC and Zn(II) ions. Binding of a single Zn(II) ion to the PrPC N-terminal domain via four His residues from the octarepeat region induces a structural transition in the C-terminal α-helices 2 and 3, promotes interaction between the N-terminal and C-terminal domains, reduces the folded protein size, and modifies the internal structural dynamics. As our results suggest that PrPC can bind Zn(II) under physiological conditions, these effects could be important for the physiological function of PrPC.
- 4 November 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-15
Open AccessZn(II) binding causes interdomain changes in the structure and flexibility of the human prion protein
The cellular prion protein (PrPC) is a mainly α-helical 208-residue protein located in the pre- and postsynaptic membranes. For unknown reasons, PrPC can undergo a structural transition into a toxic, β-sheet rich scrapie isoform (PrPSc) that is responsible for transmissible spongiform encephalopathies (TSEs). Metal ions seem to play an important role in the structural conversion. PrPC binds Zn(II) ions and may be involved in metal ion transport and zinc homeostasis. Here, we use multiple biophysical techniques including optical and NMR spectroscopy, molecular dynamics simulations, and small angle X-ray scattering to characterize interactions between human PrPC and Zn(II) ions. Binding of a single Zn(II) ion to the PrPC N-terminal domain via four His residues from the octarepeat region induces a structural transition in the C-terminal α-helices 2 and 3, promotes interaction between the N-terminal and C-terminal domains, reduces the folded protein size, and modifies the internal structural dynamics. As our results suggest that PrPC can bind Zn(II) under physiological conditions, these effects could be important for the physiological function of PrPC.
- Open Access
The engineered peptide construct NCAM1-Aβ inhibits aggregation of the human prion protein (PrP)
In prion diseases, the prion protein (PrP) becomes misfolded and forms fibrillar aggregates, which are resistant to proteinase degradation and become responsible for prion infectivity and pathology. So far, no drug or treatment procedures have been approved for prion disease treatment. We have previously shown that engineered cell-penetrating peptide constructs can reduce the amount of prion aggregates in infected cells. The molecular mechanisms underlying this effect are however unknown. Here, we use atomic force microscopy (AFM) imaging to show that the aggregation of the human PrP protein can be inhibited by equimolar amounts of the 25 residues long engineered peptide construct NCAM1-Aβ.
Open AccessThe engineered peptide construct NCAM1-Aβ inhibits aggregation of the human prion protein (PrP)
In prion diseases, the prion protein (PrP) becomes misfolded and forms fibrillar aggregates, which are resistant to proteinase degradation and become responsible for prion infectivity and pathology. So far, no drug or treatment procedures have been approved for prion disease treatment. We have previously shown that engineered cell-penetrating peptide constructs can reduce the amount of prion aggregates in infected cells. The molecular mechanisms underlying this effect are however unknown. Here, we use atomic force microscopy (AFM) imaging to show that the aggregation of the human PrP protein can be inhibited by equimolar amounts of the 25 residues long engineered peptide construct NCAM1-Aβ.
- 1 March 2017
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 14 (3) , 345-351
Electrochemical Biosensor for the Detection of Glycated Albumin
Background: Alzheimer’s disease (AD) is the most common form of dementia. The process of AD can begin 20 years before any symptom of cognitive loss. Thus, the development of systems for early diagnosis and prevention is very important. The mechanism of AD is still under debate. Nevertheless, higher levels of glycated albumin in cerebrospinal fluid and plasma are observed in AD patients. Therefore, glycated albumin could be a biomarker of AD development. Methods: Electrochemical biosensor for direct determination of glycated albumin was based on thiol derivative of pentetic acid (DTPA) complex with Cu(II) created on gold electrode surface. His-tagged domains of Receptors for Advanced Glycation End Products (RAGE) were applied as analytical active element for glycated albumin recognition. The binding of glycated albumin by His6- RAGE domains was monitored using Osteryoung square - wave voltammetry. Results: Electrodes modified with His6 - RAGE VC1 natural domain generated decrease of Cu(II) redox currents in the presence of glycated albumin. Human albumin, Aβ 1-40 and S100B protein caused negligible influence on biosensors responses towards glycated albumin. The detection limits were: 2.3 pM, 1.1 pM, 2.9 pM and 3.1 pM in the presence of: buffer, buffer + albumin, buffer + S100B, buffer + Aβ1-40 , respectively. Conclusion: The presented electrochemical biosensor was successfully applied for the determination of glycated albumin. Considering analytical parameters such as good selectivity and sensitivity in pM range, biosensor could be recommended as an analytical tool for medical samples analysis.
- 1 March 2017
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 14 (3) , 345-351
Electrochemical Biosensor for the Detection of Glycated Albumin
Background: Alzheimer’s disease (AD) is the most common form of dementia. The process of AD can begin 20 years before any symptom of cognitive loss. Thus, the development of systems for early diagnosis and prevention is very important. The mechanism of AD is still under debate. Nevertheless, higher levels of glycated albumin in cerebrospinal fluid and plasma are observed in AD patients. Therefore, glycated albumin could be a biomarker of AD development. Methods: Electrochemical biosensor for direct determination of glycated albumin was based on thiol derivative of pentetic acid (DTPA) complex with Cu(II) created on gold electrode surface. His-tagged domains of Receptors for Advanced Glycation End Products (RAGE) were applied as analytical active element for glycated albumin recognition. The binding of glycated albumin by His6- RAGE domains was monitored using Osteryoung square - wave voltammetry. Results: Electrodes modified with His6 - RAGE VC1 natural domain generated decrease of Cu(II) redox currents in the presence of glycated albumin. Human albumin, Aβ 1-40 and S100B protein caused negligible influence on biosensors responses towards glycated albumin. The detection limits were: 2.3 pM, 1.1 pM, 2.9 pM and 3.1 pM in the presence of: buffer, buffer + albumin, buffer + S100B, buffer + Aβ1-40 , respectively. Conclusion: The presented electrochemical biosensor was successfully applied for the determination of glycated albumin. Considering analytical parameters such as good selectivity and sensitivity in pM range, biosensor could be recommended as an analytical tool for medical samples analysis.
- Open Access
- 9 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0154822
An Interplay of S-Nitrosylation and Metal Ion Binding for Astrocytic S100B Protein
Mammalian S100B protein plays multiple important roles in cellular brain processes. The protein is a clinically used marker for several pathologies including brain injury, neurodegeneration and cancer. High levels of S100B released by astrocytes in Down syndrome patients are responsible for reduced neurogenesis of neural progenitor cells and induction of cell death in neurons. Despite increasing understanding of S100B biology, there are still many questions concerning the detailed molecular mechanisms that determine specific activities of S100B. Elevated overexpression of S100B protein is often synchronized with increased nitric oxide-related activity. In this work we show S100B is a target of exogenous S-nitrosylation in rat brain protein lysate and identify endogenous S-nitrosylation of S100B in a cellular model of astrocytes. Biochemical studies are presented indicating S-nitrosylation tunes the conformation of S100B and modulates its Ca2+ and Zn2+ binding properties. Our in vitro results suggest that the possibility of endogenous S-nitrosylation should be taken into account in the further studies of in vivo S100B protein activity, especially under conditions of increased NO-related activity.
- 9 May 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0154822
Open AccessAn Interplay of S-Nitrosylation and Metal Ion Binding for Astrocytic S100B Protein
Mammalian S100B protein plays multiple important roles in cellular brain processes. The protein is a clinically used marker for several pathologies including brain injury, neurodegeneration and cancer. High levels of S100B released by astrocytes in Down syndrome patients are responsible for reduced neurogenesis of neural progenitor cells and induction of cell death in neurons. Despite increasing understanding of S100B biology, there are still many questions concerning the detailed molecular mechanisms that determine specific activities of S100B. Elevated overexpression of S100B protein is often synchronized with increased nitric oxide-related activity. In this work we show S100B is a target of exogenous S-nitrosylation in rat brain protein lysate and identify endogenous S-nitrosylation of S100B in a cellular model of astrocytes. Biochemical studies are presented indicating S-nitrosylation tunes the conformation of S100B and modulates its Ca2+ and Zn2+ binding properties. Our in vitro results suggest that the possibility of endogenous S-nitrosylation should be taken into account in the further studies of in vivo S100B protein activity, especially under conditions of increased NO-related activity.
- Open Access
Voltammetric Detection of S100B Protein Using His-Tagged Receptor Domains for Advanced Glycation End Products (RAGE) Immobilized onto a Gold Electrode Surface
In this work we report on an electrochemical biosensor for the determination of the S100B protein. The His-tagged VC1 domains of Receptors for Advanced Glycation End (RAGE) products used as analytically active molecules were covalently immobilized on a monolayer of a thiol derivative of pentetic acid (DPTA) complex with Cu(II) deposited on a gold electrode surface. The recognition processes between the RAGE VC1 domain and the S100B protein results in changes in the redox activity of the DPTA-Cu(II) centres which were measured by Osteryoung square-wave voltammetry (OSWV). In order to verify whether the observed analytical signal originates from the recognition process between the His6–RAGE VC1 domains and the S100B protein, the electrode modified with the His6–RAGE C2 and His6–RAGE VC1 deleted domains which have no ability to bind S100B peptides were applied. The proposed biosensor was quite sensitive, with a detection limit of 0.52 pM recorded in the buffer solution. The presence of diluted human plasma and 10 nM Aβ1-40 have no influence on the biosensor performance.
Open AccessVoltammetric Detection of S100B Protein Using His-Tagged Receptor Domains for Advanced Glycation End Products (RAGE) Immobilized onto a Gold Electrode Surface
In this work we report on an electrochemical biosensor for the determination of the S100B protein. The His-tagged VC1 domains of Receptors for Advanced Glycation End (RAGE) products used as analytically active molecules were covalently immobilized on a monolayer of a thiol derivative of pentetic acid (DPTA) complex with Cu(II) deposited on a gold electrode surface. The recognition processes between the RAGE VC1 domain and the S100B protein results in changes in the redox activity of the DPTA-Cu(II) centres which were measured by Osteryoung square-wave voltammetry (OSWV). In order to verify whether the observed analytical signal originates from the recognition process between the His6–RAGE VC1 domains and the S100B protein, the electrode modified with the His6–RAGE C2 and His6–RAGE VC1 deleted domains which have no ability to bind S100B peptides were applied. The proposed biosensor was quite sensitive, with a detection limit of 0.52 pM recorded in the buffer solution. The presence of diluted human plasma and 10 nM Aβ1-40 have no influence on the biosensor performance.
- Open Access
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (48) , 40457-40470
Post-translational S-Nitrosylation Is an Endogenous Factor Fine Tuning the Properties of Human S100A1 Protein
- 1 November 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (48) , 40457-40470
Open AccessPost-translational S-Nitrosylation Is an Endogenous Factor Fine Tuning the Properties of Human S100A1 Protein